A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

NCT03209973 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Classical Hodgkin Lymphoma

Interventions

DRUG: Tislelizumab

Sponsor

BeiGene